



# European Reference Network

for rare or low prevalence  
complex diseases


🌐 **Network**  
Vascular Diseases  
(VASCERN)

## VASCERN DO'S AND DON'TS FACTSHEETS FOR RARE VASCULAR DISEASE PATIENTS FACING FREQUENT SITUATIONS

**Marfan  
syndrome  
and related  
disorders**  
(HTAD-WG)

**Vascular  
Ehlers-Danlos  
syndrome**  
(MSA-WG)

**Hereditary  
Haemorrhagic  
Telangiectasia**  
(HHT-WG)



# VASCERN

VASCERN, the European Reference Network on Rare Multisystemic Vascular Diseases, is dedicated to gathering the best expertise in Europe in order to provide accessible cross-border healthcare to patients with rare vascular diseases (an estimated 1.3 million concerned). These include arterial disease (affecting aorta to small arteries), arterio-venous anomalies, venous malformations, and lymphatic diseases.

VASCERN currently consists of 31 highly specialised multidisciplinary Healthcare Providers (HCPs) from 11 EU Member States and of various European Patient Organisations and is coordinated in Paris, France.

Through our 5 Rare Disease Working Groups (RDWGs) as well as several thematic WGs and the ePAG – European Patient Advocacy Group, we aim to improve care, promote best practices and guidelines, reinforce research, empower patients, provide training for healthcare professionals and realise the full potential of European cooperation for specialised healthcare by exploiting the latest innovations in medical science and health technologies.

More information available at: <https://vascern.eu>

Follow us on [Twitter](#), [Facebook](#), [YouTube](#) and [LinkedIn](#)

# TABLE OF CONTENTS

## Marfan syndrome and related disorders

List of abbreviations.....	5	Aortic dissection.....	18
Introduction.....	6	Extra-aortic peripheral arterial dissection.....	19
Pregnancy, delivery and postpartum care		Pulmonary embolism.....	20
1.1 Before Pregnancy.....	7	Fibroscope.....	21
1.2 During Pregnancy.....	8	Glaucoma.....	22
1.3 Delivery.....	9	Spontaneous haemoperitoneum.....	23
1.4 Postpartum care.....	10	Infiltrations.....	24
Physical activity.....	11	Contraindicated medicines.....	25
Anaesthesia.....	12	Odontology/Dentistry.....	26
Antiplatelet agents and anticoagulants.....	13	Pneumothorax.....	27
Stroke.....	14	Acute coronary syndrome.....	28
Orthopaedic surgery.....	15	Abdominal/gastrointestinal/gynaecological emergencies.....	29
Colonoscopy, gastroscopy and laparoscopy.....	16	Editorial Board/Contributors.....	30
Retinal detachment.....	17		

## Vascular Ehlers-Danlos syndrome

List of abbreviations.....	33	<b>Pregnancy, Delivery and Postpartum care</b>	
Introduction.....	34	Pregnancy.....	48
Factsheets.....	35	Delivery.....	49
<b>Complications in vEDS</b>		Breastfeeding.....	50
Peripheral arterial dissection.....	37	<b>Invasive investigations and treatment of common medical emergencies in vEDS</b>	
Abdominal emergencies.....	38	Colonoscopy.....	52
Haemoperitoneum.....	40	Pulmonary embolism.....	53
Arterial revascularisation.....	41	Venous Thrombosis.....	54
Aortic dissection.....	42	Antiplatelet agents and anticoagulants.....	55
Acute coronary syndrome.....	43	<b>Exercise</b> .....	56
Carotid-cavernous fistulas.....	44	References.....	57
Pneumothorax.....	45	Editorial Board/Contributors.....	58
Stroke.....	46		

## Hereditary Haemorrhagic Telangiectasia

List of abbreviations.....	61	Brain abscesses.....	69
Introduction.....	62	Heart failure.....	70
Physical activity.....	63	Kidney failure.....	71
Breast feeding.....	64	Care for patient with multiple traumatic injuries.....	72
Contraindicated medications.....	65	Bronchoscopies.....	73
Antiplatelet agents (APA) and anticoagulants.....	66	Aortic dissection.....	74
Deep-vein thrombosis pulmonary embolism.....	67	Editorial Board/Contributors.....	75
Haemorrhagic stroke.....	68		



**European  
Reference  
Network**

for rare or low prevalence  
complex diseases

**Network**  
Vascular Diseases  
(VASCERN)

# Marfan syndrome and related disorders

---



# Abbreviations

**HTAD-WG:** Heritable Thoracic Aortic Diseases Working Group

**MFS:** Marfan syndrome

**IVF:** In vitro fertilization

**βblockers:** beta-blockers

# Introduction

These factsheets are based on existing French factsheets which have been reviewed and adjusted by the experts of the VASCERN HTAD-WG.

The HTAD-WG agrees with the recommendations but wishes to emphasize that these are recommendations made by consensus at expert level. We would recommend that these factsheets be used as a guide to implement locally agreed policies.

These factsheets are meant for patients as well as for caregivers. Implementing these recommendations should go hand in hand with strategies to educate patients about medical situations where specific care is required and about relevant symptoms and how to act when they occur.

# Pregnancy, delivery and postpartum care

## 1.1 Before Pregnancy



### WHAT IS RECOMMENDED

---

- Address the issue of pregnancy in both male and female Marfan syndrome (MFS) patients of childbearing age in a systematic manner to inform them of the options of prenatal/pre-implantation diagnostics. Inform women as well about specific management and care recommendations - also include the optimal conditions of follow-up and a written delivery plan.
- As soon as a pregnancy is being considered by someone suspected of having MFS, refer him and/or her to a specialized centre, if this has not already been done, for a full assessment and pre-pregnancy counselling.
- Plan the pregnancy in collaboration with the specialized centre.
- Assess the risk of aortic dissection before pregnancy by measuring the aortic diameter.
- <40 mm: pregnancy allowed.
- 40-45 mm: pregnancy allowed on a case by case basis.
- >45 mm: contra-indication for pregnancy with limited evidence. This aortic diameter may warrant prior surgery.
- No data is available on the effect of hormonal procedures (IVF). The same thresholds as for pregnancy (contra-indicated when ARD >45 mm) should be used.

# Pregnancy, delivery and postpartum care

## 1.2 During Pregnancy

The risk of aortic dissection is increased during pregnancy, delivery and the postpartum period



### WHAT IS RECOMMENDED

---

- Treatment with  $\beta$ blockers throughout the entire pregnancy and in the postpartum period. Check the type of  $\beta$ blocker: atenolol is the least favourable; propranolol, metoprolol and labetalol are preferred.
- Monitor the aortic diameters (including abdominal diameters) by ultrasound at least twice during pregnancy: 20-24w and 32-36w. More examinations may be considered if the aortic diameter is above 40 mm or when increased growth is noted.
- Monitor blood pressure on a regular basis (target <130/80 mm Hg).
- Foetal growth should be monitored carefully to assess the effect of  $\beta$ blockers.



### WHAT YOU SHOULD NOT DO

---

- Prohibit pregnancy for all women with Marfan Syndrome.
- Stop treatment with beta-blockers during the pregnancy or at delivery.



# Pregnancy, delivery and postpartum care

## 1.3 Delivery



### WHAT IS RECOMMENDED

---

- Assess the risk of aortic dissection before delivery based on the aortic diameter.
- <40mm: vaginal delivery. Shorten the duration of stage 2 of labour with vacuum extractors, etc.
- 40-45 mm: delivery on a case by case basis (contact the expert centre).
- >45 mm: Caesarean section and plan the delivery by limiting the duration of the third trimester, the period of maximum risk.
- A tailored delivery should be formalized. Different factors should be taken into account: distance of home to hospital, aortic diameter, etc... Labour should be limited to a minimum.
- Adequate epidural anesthesia should be performed with caution, considering dural leakage and in some cases dose adjustment.



### WHAT YOU SHOULD NOT DO

---

- Administer an epidural without first checking the condition of the spine (scoliosis, spondylolisthesis, dural ectasia).
- Stop treatment with  $\beta$ blockers.
- Prescribe beta-mimetics.

# Pregnancy, delivery and postpartum care

## 1.4 Postpartum care



### WHAT IS RECOMMENDED

---

- Cardiac ultrasound in the mother within 48 hours postpartum and after 6 weeks.
- Depending on the heart rate of the baby at birth, additional monitoring can be decided by the paediatrician.

#### **Breastfeeding**

- Breastfeeding is not contraindicated.

# Physical activity

Sports can be of great value considering body weight, blood pressure and fitness of the patient. Many symptoms like aches, pains and migraines may benefit from exercise. Sports can also be dangerous if they are accompanied by a significant increase in arterial blood pressure or if there is a risk of impact (to the eye in particular).



### WHAT IS RECOMMENDED

---

- Endurance sports such as swimming, walking, running, and cycling.
- The physical activity level should be adjusted by the cardiologist based on the evaluation of aortic dimensions and valvular function, both in children and adults.



### WHAT YOU SHOULD NOT DO

---

- Abrupt, isometric exercises, such as weightlifting, football, basketball, handball, and tennis.
- Expose oneself to the risk of bodily collisions which could increase the likelihood of ectopia lentis.

# Anaesthesia

General anaesthesia does not pose any particular problems, apart from an interaction with  $\beta$ blocker treatment or anticoagulants ([www.orphananaesthesia.eu](http://www.orphananaesthesia.eu)).



### WHAT YOU SHOULD NOT DO

---

- Expose the patient to blood pressure fluctuations.

# Antiplatelet agents and anticoagulants



### WHAT IS RECOMMENDED

---

- Indications and contraindications for antiplatelet and anticoagulant treatments are identical in Marfan and non-Marfan patients.



### WHAT YOU SHOULD NOT DO

---

- Modify the prescription of antiplatelet agents or anticoagulants as a result of a diagnosis with Marfan Syndrome.

# Stroke

The incidence of stroke is not increased in patients with Marfan Syndrome.



### WHAT IS RECOMMENDED

---

- Rule out aortic dissection with extension to the supra-aortic trunks.
- Management and treatment are identical for Marfan and non-Marfan patients.



### WHAT YOU SHOULD NOT DO

---

- Stop treatment with  $\beta$ blockers.
- Delay management and treatment as a result of a diagnosis of Marfan Syndrome.

# Orthopaedic surgery



### WHAT YOU SHOULD NOT DO

---

- Stop  $\beta$ blockers - expose the patient to blood pressure fluctuations.

# Colonoscopy, gastroscopy and laparoscopy

No particular issues except in cases with dissection of the descending aorta.



### WHAT IS RECOMMENDED

---

- A high degree of caution in cases with dissection of the descending aorta due to the high risk of blood pressure variations.



### WHAT YOU SHOULD NOT DO

---

- Expose the patient to blood pressure fluctuations.



# Retinal detachment

There are no specific issues with management and treatment even though patients have a higher incidence of retinal detachment.

# Aortic dissection



### WHAT IS RECOMMENDED

---

- Consider aortic dissection if chest pain/back pain/abdominal pain is present in a patient with Marfan syndrome or a Marfan-related syndrome.
- Treat the dissection as an emergency, following the same protocols as with a non-Marfan patient.



### WHAT YOU SHOULD NOT DO

---

- Use a stent as a first option in the presence of a dissection of the descending aorta.

# Extra-aortic peripheral arterial dissection



## WHAT IS RECOMMENDED

---

- Ensure that there is no evidence of aortic dissection.

# **Pulmonary embolism**

Thrombolysis is not contraindicated.



## **Marfan syndrome and related disorders**

---

# **Fibroscopy**

No specific recommendations.



## Marfan syndrome and related disorders

---

# Glaucoma

Glaucoma is potentially related to lens dislocation.  
Check the position of the lens.

# Spontaneous haemoperitoneum

Thrombolysis is not contraindicated.



## **WHAT IS RECOMMENDED**

---

- Rule out aortic dissection.



## **Marfan syndrome and related disorders**

---

# **Infiltrations**

No particular issues except in cases of anticoagulant treatment.



# Contraindicated medications

There are no specific contraindications to Bromocriptin, or any other drug, in patients with Marfan syndrome



### WHAT IS RECOMMENDED

---

- QT prolongation should be checked on the electrocardiography prior to proposing QT prolonging drugs.

# Odontology/Dentistry

No specific issues with management and treatment, even though patients have a very narrow jaw.



### WHAT IS RECOMMENDED

---

- Regular monitoring.
- Early orthodontic follow-up due to dental misalignments.
- The prevention of endocarditis, as in the general population (only in the case of a history of valve surgery or if previous history of endocarditis).

# Pneumothorax

No particular issues except in cases of anticoagulant treatment.



### WHAT IS RECOMMENDED

---

- Indications and treatments are identical for Marfan and non-Marfan patients.
- Perform aortic imaging if there is the slightest suspicion of aortic dissection.



### WHAT YOU SHOULD NOT DO

---

- Stop treatment with  $\beta$ blockers.
- Delay care as a result of the diagnosis of Marfan syndrome.

# Acute coronary syndrome



## WHAT IS RECOMMENDED

---

- A coronary dissection may be seen in syndromes related to Marfan Syndrome, and this diagnosis should be considered in a young person.
- Ensure that there is no aortic dissection.

# Abdominal/gastrointestinal/ gynaecological emergencies

No particular issues except in cases of anticoagulant treatment.



### WHAT IS RECOMMENDED

---

- Rule out aortic dissection if there is the slightest doubt or in the event of unexplained pain.
- Indications and treatments are identical in Marfan and non-Marfan patients.



### WHAT YOU SHOULD NOT DO

---

- Administer a spinal anaesthetic without first checking the condition of the spine (scoliosis, spondylolisthesis, dural ectasia).
- Stop treatment with  $\beta$ blockers.
- Delay treatment as a result of the diagnosis of Marfan Syndrome.

# Editorial Board/ Contributors

Based on the French original document produced by: Fava-Multi  
(The French Network for Rare Vascular Diseases)



### Editorial Board:

**Prof Guillaume Jondeau**, Reference Centre for Marfan Syndrome and related disorders, Service de cardiologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris)



### Review Board from the French Marfan Network:

**Dr Laurence BAL-THEOLEYRE** (Expert Centre for Rare Vascular Diseases and Marfan Syndrome, Marseille), **Dr Claire BOULETI** (Reference Centre for Marfan Syndrome and related disorders, AP-HP, Hôpital Bichat-Claude Bernard, Paris), **Dr Yves Dulac** (Marfan Syndrome Expert Centre, Toulouse), **Dr Thomas EDOUARD** (Marfan Syndrome Expert Centre, Toulouse), **Prof Laurence FAIVRE** (Marfan Syndrome Expert Centre, Dijon), **Dr Nolwenn JEAN** (Marfan Syndrome Expert Centre, Dijon), **Dr Fabien LABOMBARDA** (Rare Vascular Diseases and Marfan Syndrome Expert Centre, Caen), **Dr Marc LAMBERT** (Expert Centre for Rare Vascular Diseases and Marfan Syndrome, Lille), **Dr Claire LE HELLO** (Rare Vascular Diseases and Marfan Syndrome Expert Centre, Caen), **Dr Olivier MILLERON** (Reference Centre for Marfan Syndrome and related disorders, AP-HP, Hôpital Bichat-Claude Bernard, Paris), **Paulette MORIN** (MARFANS Association), **Prof Sylvie ODENT** (Marfan Syndrome Expert Centre, Rennes), **Dr Julie PLAISANCIE** (Marfan Syndrome Expert Centre, Toulouse).

### With collaboration from other members of the French Marfan Network:

**Dr Pascal DELSART** (Marfan Syndrome Expert Centre - CHRU Lille), **Dr Sophie DUPUIS-GIROD** (Marfan Syndrome and HHT Expert Centre - CHU Lyon), **Dr Sébastien GAERTNER** (Marfan Syndrome Expert Centre - CHRU Strasbourg), **Dr Marie-Line JACQUEMONT** (Marfan Syndrome Expert Centre - CHU la Réunion site GHSR), **Dr Damien LANEELLE** (Marfan Syndrome Expert Centre - CHU Caen), **Dr Laurianne LE GLOAN** (Marfan Syndrome Expert Centre - CHU Nantes), **Dr Sophie NAUDION** (Marfan Syndrome Expert Centre - CHU Bordeaux), **Prof Stéphane ZUILY** (Marfan Syndrome Expert Centre - CHRU Nancy).

# Marfan syndrome and related disorders

## English version translated by VASCERN and updated by members of the VASCERN HTAD-WG:

**Prof Eloisa ARBUSTINI** (VASCERN HTAD European Reference Centre, Center for Inherited Cardiovascular Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy)

**Dr Kalman BENKE** (VASCERN HTAD European Reference Centre, Semmelweis University, Heart and Vascular Center, Budapest, Hungary)

**Dr Erik BJORCK** (VASCERN HTAD European Reference Centre, Clinical Genetics, Karolinska University Hospital Stockholm, Sweden)

**Prof Julie De BACKER** (VASCERN HTAD European Reference Centre, Dept of Cardiology and Center for Medical Genetics Ghent, Ghent University Hospital, Belgium)

**Dr Yaso EMMANUEL** (VASCERN HTAD European Reference Centre, South East Thames Regional Genetics Service, Guy's Hospital, London, UK)

**Prof Maarten GROENINK** (VASCERN HTAD European Reference Centre, Department of Cardiology, Academic Medical Center, Amsterdam, Netherlands)

**Prof Guillaume JONDEAU** (VASCERN HTAD European Reference Centre, CRMR Marfan Syndrome and related disorders, Service de cardiologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France)

**Dr Marlies KEMPERS** (VASCERN HTAD European Reference Centre, Clinical Genetics, Radboud university medical center, Nijmegen, Netherlands)

**Prof Bart LOEYS** (VASCERN HTAD European Reference Centre, Center of Medical Genetics, University Hospital of Antwerp University of Antwerp, Belgium)

**Prof Barbara MULDER** (VASCERN HTAD European Reference Centre, Department of Cardiology, Academic Medical Center, Amsterdam, Netherlands)

**Lise MURPHY** (Swedish Marfan Organisation)

**Prof Guglielmina PEPE** (VASCERN HTAD European Reference Centre, Regional Tuscany Reference Center for Marfan Syndrome and related disorders, Careggi Hospital, University of Florence, Italy)

**Dr Alessandro PINI** (VASCERN HTAD European Reference Centre, Centro Malattie Rare Cardiologiche – Marfan Clinic, Azienda Socio Sanitaria Territoriale Fatebenefratelli – Sacco Milan, Italy)

**Dr Leema ROBERT** (VASCERN HTAD European Reference Centre, South East Thames Regional Genetics Service, Guy's Hospital, London, UK)

**Prof Jolien ROOS-HESELINK** (VASCERN HTAD European Reference Centre, Clinical Genetics and Cardiology, Erasmus Medical Center Rotterdam, The Netherlands)

**Prof Zoltan SZABOLCS** (VASCERN HTAD European Reference Centre, Semmelweis University, Heart and Vascular Center, Budapest, Hungary)

**Dr Ingrid VAN DE LAAR** (VASCERN HTAD European Reference Centre, Clinical Genetics and Cardiology, Erasmus Medical Center Rotterdam, The Netherlands)

**Prof Yskert VON KODOLITSCH** (VASCERN HTAD European Reference Centre, Department of Vascular Medicine, Department of General and Interventional Cardiology, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf)

**Liesbeth WILDERO VAN WOUWE** (VASCERN HTAD European Reference Centre, VASCERN HTAD European Reference Centre, Dept of Cardiology and Center for Medical Genetics Ghent, Ghent University Hospital, Belgium)



**European  
Reference  
Network**

for rare or low prevalence  
complex diseases

**Network**  
Vascular Diseases  
(VASCERN)

# Vascular Ehlers-Danlos syndrome

---





# Abbreviations

**CTA:** Computed tomography angiography

**EDS:** Ehlers-Danlos syndrome

**GPII $\beta$ /III $\alpha$ :** Glycoprotein II beta/III alpha

**LOVD:** Leiden Open Variation Database

**MRA:** Magnetic Resonance Angiography

**MSA-WG:** Medium-Sized Arteries Working Group

**SVI:** Superficial venous insufficiency

**vEDS:** Vascular Ehlers-Danlos syndrome

# Introduction

Vascular EDS (OMIM #130050) is a rare disorder that results from heterozygosity for mutations in COL3A1 which encodes the pro- $\alpha$ 1 chains of the type III procollagen homotrimer. The condition is dominantly inherited but asymptomatic parental mosaicism can result in sib recurrence to normal parents. Arterial fragility, bowel rupture, and pregnancy complications are the major clinical complications and may limit survival to about 50 years.

Molecular diagnostic testing is therefore a key factor in identifying patients for appropriate management. More than 600 COL3A1 genetic variants are registered in the EDS database of the LOVD system, a large majority of them being private (<http://www.lovd.nl/>). This genetic testing requires having access to a genetic laboratory with experience to test and interpret COL3A1 variants, since not all variants are pathogenic and since those leading to haploinsufficiency result in a better prognosis than those with missense variants at a glycine residue or splice-site variants (Frank et al, 2015).

Clinical evaluation is usually undertaken in expert centres with the involvement of a multidisciplinary team familiar with the clinical features of this condition in probands and their first degree relatives. This rare disease suffers from lack of recognition since the main clinical diagnostic criteria for vEDS are nonspecific (hematomas, skin transparency, arterial events) and it is their association that is suggestive.

Major and minor clinical diagnostic criteria of the 2017 International classification of EDS illustrate the variety of physical signs that may constitute the clinical phenotype, adding to the diversity of arterial and visceral events during the natural course of the disease.

Because of the number of affected tissues, clinical evaluation often involves: cardiologists, clinical geneticists, vascular and interventional radiologists, ophthalmologists, orthopaedicians, physiotherapists, bowel surgeons, and vascular, endovascular and cardiac surgeons. Regular MDT meetings with multiprofessional team involvement will also aid in coordinating care of these patients. Appropriate transition of care of patients from paediatric to adult care is also essential in the care of these patients.

Genetic counselling, pre-pregnancy counselling and management during pregnancy by specialist fetal maternal teams will also be an essential part of the care of pregnant women with this disorder. Provision of appropriate counselling for family planning will also be necessary as pregnancy is associated with death in about 5% of women.

Treatment is largely mechanical, surveillance is not universally adopted, and treatment with antihypertensive agents may provide a measure of protection from arterial rupture. Medical therapy with celiprolol (particular beta-blocker) has shown its efficacy in reducing morbid cardiovascular events in a small group of patients, but there are still unmet medical needs. The need for detailed studies of natural history and mechanistic evaluation of arterial rupture are clear and probably the only way to identify helpful interventions.

# Factsheets

These factsheets are based on existing French factsheets which have been reviewed and revised by the VASCERN MSA-WG members.

The MSA-WG wishes to emphasize that these are recommendations made by consensus at expert level. We would recommend that these factsheets be used as a guide to implement locally agreed policies.

These factsheets are meant for patients as well as for caregivers. Implementing these recommendations should go hand in hand with strategies to educate patients about medical situations where specific care is required and about relevant symptoms & how to act when they occur.

# Complications in vEDS

Major life limiting complications are due to the increased risk of arterial ruptures. In these cases, urgent repair by any possible means is required. Locations that are commonly symptomatic are iliac and femoral arteries, mesenteric and celiac vessels, renal arteries, aorta (any location), and peripheral arteries of the limbs.

# Peripheral arterial dissection

Peripheral arterial dissections, especially those of the medium-sized arteries, are the most frequent complication of vascular Ehlers-Danlos syndrome. They are spontaneous and must be suspected in the presence of an unexplained pain syndrome.



### WHAT IS RECOMMENDED

---

- Call the national centre of reference or the regional centre of competence to seek advice due to the seriousness of the risk of dissection.
- Quickly implement all necessary actions in order to confirm the diagnosis of vascular Ehlers-Danlos Syndrome.
- Preference should be given to non-invasive examinations (such as MRA or CTA) and medical/conservative treatment whenever possible.
- When an arteriography is necessary (rupture, perforation), particular precaution should be taken when the guide is being moved upwards (due to risk of dissection/arterial perforation) and enhanced monitoring of the femoral insertion point is necessary.
- Arterial ruptures should be treated in preference by embolization.
- A protocol of permissive hypotension is recommended without compromise to organ function.
- Caution with use of inotropes is recommended.
- Caution with use of indwelling catheters is advised.



### WHAT YOU SHOULD NOT DO

---

- The insertion of stents (except in the case of a life-threatening emergency) should be avoided.
- Consider surgical treatment, other than as a last resort.
- Systematically initiate treatment with anticoagulation and/or antiplatelet agents.

# Abdominal emergencies

Vascular Ehlers-Danlos syndrome predisposes young adults to a high risk of digestive tract events which can be life-threatening. Bowel rupture is uncommon in early childhood, has been described in late childhood, and continues to be a risk into adulthood. Bowel rupture ultimately affects about 25–30% of individuals but rarely leads to death.

**The main abdominal emergencies are (in order of severity):**

- spontaneous arterial rupture in the peritoneal and/or retroperitoneal cavity,
- spontaneous digestive tract perforation, most often of the sigmoid colon, but also of the rest of the colon, the small intestine, and even the stomach,
- spontaneous rupture of an intra-abdominal organ (spleen, liver).



## WHAT IS RECOMMENDED

---

- Perform an emergency angiography scan in the presence of an acute abdominal syndrome.
- In the event of colonic perforation, a wide colonic resection is the preferred method of treatment (Hartmann type for sigmoid colon).
- In cases of arterial rupture, percutaneous embolization should be preferred over open surgery.
- The use of stents should be limited to life-threatening emergencies, and embolization preferred whenever possible.
- In cases of spontaneous perforation of the digestive tract in a young adult or a child, a diagnosis of vascular Ehlers-Danlos syndrome should be automatically considered.
- A protocol of permissive hypotension is recommended without compromise to organ function.
- Caution with use of inotropes is recommended.
- Caution with use of indwelling catheters is advised.

# Abdominal emergencies



## WHAT YOU SHOULD NOT DO

---

- Attempt a minimal repair of a spontaneous perforation of the digestive tract.
- Perform a postoperative follow-up colonoscopy in the event of perforation of the digestive tract.
- Perform open surgery as first-line treatment in cases with arterial rupture.
- Any invasive or semi-invasive examination, particularly when the expected diagnostic rewards are minimal.

# Haemoperitoneum

Haemoperitoneum is the cardinal indicator of acute bleeding in the abdominal cavity and requires emergency care.



### WHAT IS RECOMMENDED

---

- Perform an emergency abdominal angiography scan to look for an arterial rupture, a digestive tract perforation or an intra-abdominal organ rupture.
- In the event of an arterial rupture, selective embolization should be preferred over open surgery.
- A protocol of permissive hypotension is recommended without compromise to organ function.
- Caution with use of inotropes is recommended.
- Caution with use of indwelling catheters is advised.



### WHAT YOU SHOULD NOT DO

---

- Anticoagulant and antiplatelet treatments are associated with the occurrence of haemoperitoneum, in particular in the post-operative digestive period. In order to limit the risk of complications, these treatments should be taken for the shortest duration possible.
- Avoid unnecessary arterial puncture.



# Arterial revascularisation

Arterial events (dissections, aneurysms) are the most frequent complications of vascular Ehlers-Danlos syndrome. Most often, the arterial events are treated medically and therefore do not require intervention, such as surgery.



### WHAT IS RECOMMENDED

---

- Give preference to medical management and treatment for arterial events whenever possible.
- In the event of arterial rupture, emergency arteriography with embolization should be preferred, ideally in a specialised centre with prior experience in dealing with patients with vascular EDS.
- A protocol of permissive hypotension is recommended without compromise to organ function.
- Caution with use of inotropes is recommended.
- Caution with use of indwelling catheters is advised.



### WHAT YOU SHOULD NOT DO

---

- Treat an arterial rupture by surgical means in an emergency context, except in the case of salvage surgery. In this case, special precautions with vascular clamping and sutures are required.
- In the event of an emergency surgical procedure, simple procedures (ligatures) are to be preferred over complex vascular reconstruction.

# Aortic dissection

Taking into account the arterial fragility which is characteristic of the disease, the occurrence of a dissection and, rarely, the rupture of the aorta are the possible complications. However, these arterial accidents occur in the abdominal aorta more often than the thoracic aorta.



### WHAT IS RECOMMENDED

---

- If an acute chest and/or abdominal pain syndrome is present, it is imperative to urgently check for the presence of a dissection or rupture of the aorta.
- Give preference to non-invasive examinations (such as MRA or CTA) and medical treatment whenever possible.
- For type A aortic dissections, surgical treatment is indicated as the primary option.
- A protocol of permissive hypotension is recommended without compromise to organ function.
- Caution with use of inotropes is recommended.
- Caution with use of indwelling catheters is advised.



### WHAT YOU SHOULD NOT DO

---

- Use a stent as a first option in the presence of a dissection of the descending aorta; unless there is no other therapeutic alternative.

# Acute coronary syndrome

There does appear to be a slightly increased risk of acute coronary syndrome in vascular Ehlers-Danlos syndrome. Given the arterial fragility, dissection of a coronary artery may result in an acute coronary syndrome (non-atheromatous).



### WHAT IS RECOMMENDED

---

- Rule out an aortic dissection in the presence of an acute coronary syndrome in a patient with vascular Ehlers-Danlos syndrome.
- Give preference to non-invasive examinations (coronary scan) and medical treatment whenever possible.
- When a coronary angiography is necessary, particular caution should be taken when moving the guide upwards (due to risk of dissection/arterial perforation) and enhanced monitoring of the femoral insertion point is necessary.



### WHAT YOU SHOULD NOT DO

---

- Use fibrinolytic or anti GPIIb/IIIa agents as first-line treatments.
- Insertion of stents requiring dual or prolonged antiplatelet therapy should be avoided whenever possible.
- Radial coronary angiography (risk of dissection and ischemia of the hand).

# Carotid-cavernous fistulas

Carotid-cavernous fistula is a possible complication of vascular Ehlers-Danlos syndrome. It affects around 10-15% of patients with the syndrome, and consists of a rupture of the intracranial carotid artery into the main collection site of venous blood in the brain. Its spontaneous character is pathognomonic for vascular EDS.



## WHAT IS RECOMMENDED

---

- The appearance of a pulsating murmur in the auscultation of the skull or the eye will suggest the presence of a carotid-cavernous fistula. This suspicion is increased when the eye on the same side as the murmur becomes red and/or painful. Swelling around the eye may also be present.
- If a carotid-cavernous fistula is suspected, an angiography /cerebral MRI scan is recommended.
- Management and care in a neurovascular unit is required. Therapeutic occlusion of the fistula is often necessary, in spite of the inherent risk of the procedure. This procedure must be carried out in a specialist centre with the greatest possible level of experience.
- Blood pressure in particular should be closely monitored. Maintain a blood pressure target <130/80 mmHg. A protocol of permissive hypotension is recommended without compromise to organ function.
- Caution with use of inotropes is recommended.
- Caution with use of indwelling catheters is advised.



## WHAT YOU SHOULD NOT DO

---

- Delay imaging procedures which alone determine the diagnosis.
- Delay embolization when it is absolutely necessary, as it is a source of significant functional sequelae.

# Pneumothorax

Pneumothorax is frequently associated with vascular Ehlers-Danlos syndrome and is the most frequent respiratory manifestation of the disease. It can occur from adolescence onwards and sometimes precedes genetic diagnosis. Treatment usually involves the insertion of a chest tube (complete pneumothorax).



### WHAT IS RECOMMENDED

---

- In the event of a failure to remove the chest tube, a mechanical pleurodesis should be discussed at the time of the first occurrence.



### WHAT YOU SHOULD NOT DO

---

- Pleurodesis in the event of first episode without a failure to remove the chest tube.
- Pleurodesis in cases of partial or prophylactic pneumothorax with asymptomatic bullous lesions in a patient without pneumothorax.

# Stroke

Due to the vascular fragility which is characteristic of vascular Ehlers-Danlos syndrome, the cerebral arteries are often affected by complications, most commonly at the cervical level. The latter often present in the form of spontaneous dissections, which can obstruct the affected artery to varying degrees.



### WHAT IS RECOMMENDED

---

- In the event of clinical signs that may suggest a stroke, urgently carry out an imaging scan of the brain and of the cerebral arteries (angiography scan or MRI).
- Discuss with the referring team any indication of revascularisation (thrombolysis, salvage arteriography), arteriography presents a particular risk.
- Search specifically for a carotid-cavernous fistula in the event of pulsatile tinnitus, associated or not with exophthalmos.



### WHAT YOU SHOULD NOT DO

---

- An angioplasty (salvage) with stenting at the level of the arteries of the supra-aortic trunks.

**Pregnancy,  
Delivery and  
Postpartum care**

# Pregnancy

Pregnancy presents a particular risk in female patients with vascular Ehlers-Danlos syndrome. It is associated with an increased risk of pregnancy-related complications, directly related to the tissue fragility which is characteristic of the disease. Complications occur in about half the pregnancies and include premature rupture of membranes with preterm delivery, rare uterine rupture during labor, severe perineal tears, and antepartum and post-partum hemorrhage.



### WHAT IS RECOMMENDED

---

- Discuss any planned pregnancy with the medical and obstetrics referral team prior to conception,
- The occurrence of arterial or digestive system incidents may contraindicate a pregnancy.
- Discuss and suggest the possibility of performing prenatal diagnosis.
- Perform a complete arterial lesion assessment before or in early pregnancy.
- Arrange for increased monitoring of the uterine cervix, especially from the 28<sup>th</sup> week onwards.
- Maintain treatment with celiprolol, or introduce it if the pregnancy started without treatment.



### WHAT YOU SHOULD NOT DO

---

- Interrupt treatment with beta-blockers during pregnancy and the peripartum period.



# Delivery

There are no formal recommendations regarding the best method of delivery for patients with vascular Ehlers-Danlos syndrome. A caesarean section between 35 and 37 weeks of gestation is the approach adopted by the reference centre for rare vascular diseases, especially for primiparous patients with a known diagnosis.



### WHAT IS RECOMMENDED

---

- Schedule the delivery due to the elevated risk of maternal complications.
- Always recommend carrying out a caesarean section between 35 and 37 weeks of gestation.
- Plan for the birth to take place in a level 3 maternity unit.



### WHAT YOU SHOULD NOT DO

---

- Delivery at home or in a level 1-2 maternity unit.
- Vaginal delivery without prior multidisciplinary consultation.

# Breastfeeding

Vascular Ehlers-Danlos syndrome in itself is not a contraindication to breastfeeding. Nonetheless, the beta-blocker treatment prescribed to prevent the vascular complications of the disease in the mother is not generally recommended during breastfeeding as it is transmitted to the newborn through breast milk.



### WHAT IS RECOMMENDED

---

- Discuss breastfeeding on a case-by-case basis with the attending obstetric and paediatric teams.



### WHAT YOU SHOULD NOT DO

---

- Interrupt the mother's beta-blocker treatment with celiprolol in order to allow for breastfeeding.
- Consider breastfeeding when the newborn has displayed side-effects of beta-blocker use (including bradycardia, respiratory distress and/or hypoglycemia).
- Consider breastfeeding when maternal complications, related to vascular Ehlers-Danlos syndrome, have been reported in the peripartum period.

**Invasive  
investigations  
and treatment of  
common medical  
emergencies in  
vEDS**

# Colonoscopy

Colonoscopy is an invasive examination of the colon frequently performed in routine medical practice. Patients with vascular Ehlers-Danlos syndrome have a fragility of the colon which can make this examination dangerous. It is therefore in principle avoided, in order to prevent potentially serious complications.



### WHAT IS RECOMMENDED

---

- Colonoscopy screening for common diseases of the colon should be avoided.
- Colonic video capsule should be the preferred examination whenever possible over invasive exploration of the colon.



### WHAT YOU SHOULD NOT DO

---

- Perform a colonoscopy after an episode of spontaneous perforation of the colon, particularly in a patient who has previously experienced a colonic perforation.

# Pulmonary embolism

There is no particular risk of pulmonary embolism associated with vascular Ehlers-Danlos syndrome.



### WHAT IS RECOMMENDED

---

- Follow standard treatment protocols for pulmonary embolisms (anticoagulant treatment).



### WHAT YOU SHOULD NOT DO

---

- Fibrinolysis should be avoided whenever possible due to the increased risk of haemorrhage over the course of the disease.

# Venous Thrombosis

There is no particular risk of venous thrombosis associated with vascular Ehlers-Danlos syndrome. In contrast, superficial venous insufficiency (SVI) of the lower limbs is common (varicose veins), which may be a risk factor for venous thrombosis. SVI in vEDS is characterized by its onset of venous disease before the age of 20 years and the early presence of significant (>3 mm) varicose veins.



### WHAT IS RECOMMENDED

---

- Carry out a venous assessment if there are functional or physical symptoms of superficial venous insufficiency of the lower limbs.



### WHAT YOU SHOULD NOT DO

---

- Treat saphenous insufficiency by vein stripping (risk of arterial or femoral venous rupture).

# Antiplatelet agents and anticoagulants

The fragility of patients with vascular Ehlers-Danlos syndrome is not conducive to the prescription of antiplatelet and anticoagulant treatments.



### WHAT IS RECOMMENDED

---

- Discuss the prescription of antiplatelet agents / anticoagulants on a case-by-case basis.
- In all cases limit the prescription to the minimum duration necessary.
- Limit the prescription of NSAIDs and if they are necessary use only on an infrequent basis.



### WHAT YOU SHOULD NOT DO

---

- Continue antiplatelet / anticoagulant treatment over the long term, unless otherwise indicated.
- Combine anticoagulants with antiplatelets, and/or several antiplatelet agents.

# Exercise

Most of the usual aspects of daily living and recreational activities are not restricted in vEDS. The major concerns associated with high level sports activities are the risk of vascular rupture with the trauma of collisions and the change in blood pressure during these activities.



### WHAT IS RECOMMENDED

---

- Mild to moderate aerobic physical activity, where there is the capacity to converse with partner, is thought to be beneficial.
- Use of equipment such as stationary bicycles, elliptical trainers or well cushioned treadmills could be encouraged.
- Light weights to retain tone and strength and good breath control while using weights.



### WHAT YOU SHOULD NOT DO

---

- Collision sports and isometric activities are generally discouraged.
- Running on hard surfaces and for long distances may exacerbate foot, ankle, knee, and hip pain.
- Activities with rapid acceleration/deceleration should be discouraged as these may increase the risk of vessel dissection.



# References

Brooke BS, Arnaoutakis G, McDonnell NB, Black JH. 2010. Contemporary management of vascular complications associated with Ehlers-Danlos syndrome. *J Vasc Surg* 51:131-138. Discussion 138-139.

---

Frank M, Says J, Denarie N, Messas E. 2015b. Natural history of superficial venous insufficiency in patients with vascular Ehlers-Danlos syndrome. *Phleb Ann Vasc* 68:34-40.

---

Frank M, Says J, Denarie N, Sapoval M, Messas E. 2016. Successful segmental thermal ablation of varicose saphenous veins in a patient with confirmed vascular Ehlers-Danlos syndrome. *Phlebology* 31:222-224.

---

Murray ML, Pepin M, Peterson S, Byers PH. 2014. Pregnancy-related deaths and complications in women with vascular Ehlers-Danlos syndrome. *Genet Med* 16:874-880.

---

Okada T, Frank M, Pellerin O, Primio MD, Angelopoulos G, Boughenou MF, Pagny JY, Messas E, Sapoval M. 2014. Embolization of life-threatening arterial rupture in patients with vascular Ehlers-Danlos syndrome. *Cardiovasc Intervent Radiol* 37:77-84.

---

Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P. 2010. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: A prospective randomised, open, blinded endpoints trial. *Lancet* 376:1476-1484.

---

Byers PH, Belmont J, Black J, De Backer J, Frank M, Jeunemaitre X, Johnson D, Pepin M, Robert L, Sanders L, Wheeldon N. 2017. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. *American Journal of Medical Genetics Part C (Seminars in Medical Genetics)* 175C:40-47.

# Editorial Board/ Contributors

Based on the French original document produced by:  
Fava-Multi (The French Network for Rare Vascular Diseases)



### Editorial Board:

**Pr Xavier JEUNEMAITRE** and **Dr Michael FRANK**, Reference Center for Rare Vascular Diseases, HEGP Hôpital Européen Georges Pompidou



### Review Board from the French Rare Vascular Diseases Network:

**Dr Salma ADHAM** (Rare Vascular Diseases Reference Centre, HEGP, Paris), **Dr Juliette ALBUISSON** (Rare Vascular Diseases Reference Centre, HEGP, Paris), **Dr Laurence BAL-THEOLEYRE** (Expert Centre for Rare Vascular Diseases and Marfan Syndrome, Marseille), **Marie-Hélène BOUCAND** (AFSED), **Dr Olivier ESPITIA** (Rare Vascular Diseases Expert Centre, Nantes), **Dr Fabien LABOMBARDA** (Rare Vascular Diseases and Marfan Syndrome Expert Centre, Caen), **Prof Laurent LACCOUREYE** (HHT and Vascular Diseases Expert Centre, Angers), **Dr Marc LAMBERT** (Expert Centre for Rare Vascular Diseases and Marfan Syndrome, Lille), **Dr Christian LAVIGNE** (HHT and Vascular Diseases Expert Centre, Angers), **Dr Claire LE HELLO** (Rare Vascular Diseases and Marfan Syndrome Expert Centre, Caen), **Dr Jean-Michaël MAZZELLA** (Rare Vascular Diseases Reference Centre, HEGP, Paris), **Dr Tristan MIRAULT** (Rare Vascular Diseases Reference Centre, HEGP, Paris) **Dr Marc-Antoine PISTORIUS** (Rare Vascular Diseases Expert Centre, Nantes), **Dr Geoffrey URBANSKI** (HHT and Vascular Diseases Expert Centre, Angers), **Dr Stéphane VIGNES** (Rare Vascular Diseases Expert Centre, Cognacq-Jay Hospital, Paris)

# Vascular Ehlers-Danlos syndrome (vEDS)

---

## English version translated by VASCERN and updated by members of the VASCERN MSA-WG:

**Prof Julie De BACKER** (VASCERN MSA European Reference Centre, Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium)

**Dr Michael FRANK** (VASCERN MSA European Reference Centre, Rare Vascular Diseases Reference Centre, AP-HP, HEGP Hôpital Européen Georges Pompidou, Paris, France)

**Juergen GRUNERT** (Ehlers-Danlos-Initiative e.V., Germany)

**Prof Xavier JEUNEMAITRE** (VASCERN MSA European Reference Centre, Rare Vascular Diseases Reference Centre, AP-HP, HEGP Hôpital Européen Georges Pompidou, Paris, France)

**Prof Bart LOEYS** (VASCERN MSA European Reference Centre, Center of Medical Genetics, University Hospital of Antwerp, University of Antwerp, Belgium)

**Dr Alessandro PINI** (VASCERN MSA European Reference Centre, Centro Malattie Rare Cardilogiche - Marfan Clinic, Azienda Socio Sanitaria Territoriale Fatebenefratelli - Sacco, Milan, Italy)

**Dr Leema ROBERT** (VASCERN MSA European Reference Centre, South East Thames Regional Genetics Service, Guy's Hospital, London, UK)

**Prof Jolien ROOS-HESELINK** (VASCERN MSA European Reference Centre, Erasmus Medical Center, Rotterdam, Netherlands)

**Dr Ingrid VAN DE LAAR** (VASCERN MSA European Reference Centre, Erasmus Medical Center, Rotterdam, Netherlands)





**European  
Reference  
Network**

for rare or low prevalence  
complex diseases

**Network**  
Vascular Diseases  
(VASCERN)

# Hereditary Haemorrhagic Telangiectasia

---



# Abbreviations

**HHT:** Hereditary Haemorrhagic Telangiectasia

**HHT-WG:** Hereditary Haemorrhagic Telangiectasia Working Group

**APA:** Antiplatelet agent

**ENT doctor:** Ear, Nose, and Throat doctor

**AVM:** Arteriovenous malformation

**VM:** Vascular malformation

**SaO<sub>2</sub>:** Oxygen saturation

# Introduction

These factsheets are based on existing French factsheets which have been reviewed and adjusted by the experts of the VASCERN HHT-WG.

The HHT-WG agrees with the recommendations but wishes to emphasize that these are recommendations made by consensus at expert level. We would recommend that these factsheets be used as a guide to implement locally agreed policies.

These factsheets are meant for patients as well as for caregivers. Implementing these recommendations should go hand in hand with strategies to educate patients about medical situations where specific care is required and about relevant symptoms and how to act when they occur.

## Physical activity



### WHAT IS RECOMMENDED

---

- There are no physical activity or sport restrictions, except in the event of acute hypoxia.



### WHAT YOU SHOULD NOT DO

---

- Scuba diving with a diving tank in patients with pulmonary arteriovenous malformations, even if embolised (risk of air embolism).

# Breast feeding



### WHAT IS RECOMMENDED

---

- Breastfeeding is not contraindicated in women with hereditary haemorrhagic telangiectasia.



### WHAT YOU SHOULD NOT DO

---

- No specific recommendations.



# Contraindicated medications

No medication is formally contraindicated.



### WHAT IS RECOMMENDED

---

- Always discuss the risks and benefits with the centre of reference or competence responsible for the care of the patient.
- Adapt the treatment to the patient's clinical condition (epistaxis, gastrointestinal bleeding).



### WHAT YOU SHOULD NOT DO

---

- Prescribe antiplatelet agents (APAs) or anticoagulants without having weighed the potential risks and benefits.

# Antiplatelet agents (APA) and anticoagulants



### WHAT IS RECOMMENDED

---

- Discuss the risks and benefits with the centre of reference or expertise responsible for the patient.
- Adapt the treatment to the patient's clinical condition (epistaxis, gastrointestinal bleeding).
- After an ischemic stroke secondary to pulmonary arteriovenous malformations, there is no indication to continue this type of treatment (APA or anticoagulant) if all pulmonary arteriovenous malformations have been treated satisfactorily.



### WHAT YOU SHOULD NOT DO

---

- Prescribe APAs or anticoagulants without having weighed the risks and benefits.

# Deep-vein thrombosis, pulmonary embolism (or venous thromboembolic disease)

No medication is formally contraindicated.



### WHAT IS RECOMMENDED

---

- Follow the standard treatment for thrombosis and/or pulmonary embolism (anticoagulant treatment) having weighed the potential risks and benefits.
- Adapt the treatment to the patient's clinical condition (epistaxis, gastrointestinal bleeding, blood count).
- In the event of increased epistaxis while taking anticoagulation treatment, arrange for a consultation with an ENT doctor who has knowledge of the disease in order to consider appropriate treatment.
- Outside of an emergency situation, and depending on anti-coagulant tolerance, discuss alternative treatments (thrombectomy, cava filter) with the centre of reference or competence.



### WHAT YOU SHOULD NOT DO

---

- Avoid treating vascular thromboembolic disease because of hereditary haemorrhagic telangiectasia.

# Haemorrhagic stroke



### WHAT IS RECOMMENDED

---

- Emergency management and treatment (as in non-HHT patients).
- Look for underlying brain AVMs to prevent recurrence.
- If the patient's clinical condition requires the insertion of a nasogastric tube, it should be soft, of small diameter (unless clinical circumstances demand a large bore tube), and put in place with extreme caution due to the risk of triggering a severe episode of epistaxis related to the presence of mucous telangiectases.



### WHAT YOU SHOULD NOT DO

---

- No specific contraindications.

# Brain abscesses

A brain abscess is a classic complication of hereditary haemorrhagic telangiectasia. It is related to the right-to-left shunt secondary to pulmonary arteriovenous malformations.



### WHAT IS RECOMMENDED

---

- Emergency management and treatment (as in non-HHT patients).
- Perform a chest CT scan without injection, or contrast echocardiogram to identify pulmonary arteriovenous malformations (the most common cause of brain abscess in hereditary haemorrhagic telangiectasia), and treat the pulmonary arteriovenous malformations to reduce the risk of recurrence.
- If the patient's clinical condition requires the insertion of a nasogastric tube, this should be soft, of small diameter (unless clinical circumstances demand a large bore tube), and put in place with extreme caution due to the risk of triggering a severe episode of epistaxis related to the presence of mucous telangiectases.



### WHAT YOU SHOULD NOT DO

---

- No specific contraindications.

# Heart failure

Heart failure in Hereditary Haemorrhagic telangiectasia may be related to the evolution of hepatic AVMs that can entail cardiac chronic overload: both hepatic and cardiac hemodynamics must be investigated.

Medical treatment will be adapted to each particular case: treatment of heart failure, correction of anemia, management of arrhythmia.



### WHAT IS RECOMMENDED

---

- Measure cardiac output and the cardiac index, the filling pressures and the presence or absence of pulmonary hypertension (often post-capillary).
- Search for hepatic arteriovenous malformations (Doppler ultrasound and/or hepatic scan).
- Refer the patient to a centre of reference.
- Correct the anaemia.



### WHAT YOU SHOULD NOT DO

---

- Overlook cardiac evaluation (including echocardiography) if severe liver VMs are present.
- Treat pulmonary hypertension secondary to liver VMs with high output cardiac failure, with vasodilators.

# Kidney failure



### WHAT IS RECOMMENDED

---

- No contraindications to kidney biopsy puncture after exclusion of kidney AVMs by doppler sonography.



### WHAT YOU SHOULD NOT DO

---

- No specific contraindications.

# Care for patient with multiple traumatic injuries

It is always necessary to contraindicate nasal manipulations (nasal intubation, aspirations, etc.) due to the significant risk of triggering sometimes very severe episodes of epistaxis linked to mucous telangiectases.

Apart from the risk of bleeding related to the presence of mucous telangiectases (nasal, gastrointestinal), there are no coagulation anomalies associated with hereditary haemorrhagic telangiectasia and no surgical bleeding risk connected with this pathology.



### WHAT IS RECOMMENDED

---

- Check that there is no low SaO<sub>2</sub> that could be related to the presence of undiagnosed pulmonary AVMs, which would warrant treatment.



### WHAT YOU SHOULD NOT DO

---

- Intubate or aspirate through the nose: risk of severe epistaxis.



# Bronchoscopies

Be aware that coughing may be tolerated less well than in other patients due to the risk of haemoptysis from tube abrasion.



### WHAT IS RECOMMENDED

---

- Follow the standard fibroscopy technique.
- In case of biopsy, perform with antibiotic prophylaxis if pulmonary AVMs are present, or if pulmonary status is unknown.



### WHAT YOU SHOULD NOT DO

---

- Nasal manipulations during anaesthesia (nasal intubation, aspirations, etc.) due to the significant risk of triggering sometimes very severe episodes of epistaxis linked to mucous telangiectases.

# Aortic dissection

Before any surgery it is always necessary to contraindicate nasal manipulations (nasal intubation, aspirations, etc.) due to the significant risk of triggering sometimes very severe episodes of epistaxis linked to mucous telangiectases.

Apart from the risk of bleeding related to the presence of mucous telangiectases (nasal, gastrointestinal), there are no coagulation anomalies associated with hereditary haemorrhagic telangiectasia and no surgical bleeding risk connected with this pathology.



### WHAT IS RECOMMENDED

---

- Emergency management and treatment (as in non-HHT patients).
- Follow standard treatment protocols for this pathology.
- If the patient's clinical condition requires the insertion of a nasogastric tube, this should be soft, of small diameter (unless clinical circumstances demand a large bore tube), and put in place with extreme caution due to the risk of triggering a severe episode of epistaxis related to the presence of mucous telangiectases.



### WHAT YOU SHOULD NOT DO

---

- Intubate or aspirate through the nose: risk of severe epistaxis.

# Editorial Board/ Contributors

Based on the French original document produced by:  
Fava-Multi (The French Network for Rare Vascular Diseases)



### Editorial Board:

**Dr Sophie DUPUIS-GIROD**, HHT Center of Reference,  
CHU de Lyon HCL, France



### Review Board from the French HHT Network:

**Prof Brigitte GILBERT-DUSSARDIER** (HHT Expert Centre, Poitiers), **Didier ERASME** (AMRO-HHT-France),  
**Prof Laurent LACCOUREYE** (HHT and Vascular Diseases Expert Centre, Angers), **Dr Christian LAVIGNE**  
(HHT and Vascular Diseases Expert Centre, Angers), **Dr Sophie RIVIÈRE** (HHT Expert Centre Montpellier),  
**Dr Geoffrey URBANSKI** (HHT and Vascular Diseases Expert Centre, Angers)

### And other members of the French HHT Network:

**Prof Marie-France CARETTE** (HHT Expert Centre Paris – Hôpital Tenon), **Prof Thierry CHINET** (HHT Expert  
Centre Paris – Hôpital Ambroise Paré), **Dr Anne CONTIS** (HHT Expert Centre Bordeaux - Hôpital Jean  
Bernard), **Dr Romain CORRE** (HHT Expert Centre Rennes - Hôpital Pontchaillou), **Dr Pierre DUFFAU** (HHT  
Expert Centre Bordeaux - Hôpital Jean Bernard), **Xavier DUFOUR** (HHT Expert Centre Poitiers - Hôpital  
Jean Bernard), **Prof Vincent GROBOST** (HHT Expert Centre - CHU Estaing Clermont-Ferrand), **Pr Jean-  
Robert HARLE** (HHT Expert Centre Marseille - Hôpital de la Timone), **Prof Pierre-Yves HATRON** (HHT  
Expert Centre Lille -Hôpital Claude Huriez), **Dr Shirine MOHAMED** (HHT Expert Centre - CHRU Nancy), **Dr  
Pascal MAGRO** (HHT Expert Centre - Tours - Hôpital Bretonneau), **Dr Antoine PARROT** (HHT Expert Centre  
- Paris – Hôpital Tenon)

# Hereditary Haemorrhagic Telangiectasia

---

## English version translated by VASCERN and updated by members of the VASCERN HHT-WG:

**Prof Elisabetta BUSCARINI** (VASCERN HHT European Reference Centre, Maggiore Hospital, ASST Crema, Italy)

**Claudia CROCIONE** (HHT Europe/Associazione Italiana Teleangiectasia Emorragica – HHT ONLUS)

**Dr Freya DROEGE** (VASCERN HHT European Reference Centre, Essen Center for Rare Diseases, Essen University Hospital, Germany)

**Dr Sophie DUPUIS-GIROD** (VASCERN HHT European Reference Centre, CHU de Lyon HCL, France)

**Prof Anette KJELDSEN** (VASCERN HHT European Reference Centre, Odense University Hospital, Denmark)

**Dr Hans-Jurgen MAGER** (VASCERN HHT European Reference Centre, St. Antonius Hospital Nieuwegein, The Netherlands)

**Dr. Fabio PAGELLA** (VASCERN HHT European Reference Centre, Department of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy)

**Prof Carlo SABBÀ** (VASCERN HHT European Reference Centre, Azienda Ospedaliero-Universitaria Consorziale di Bari Policlinico-Giovanni XXIII, Bari, Italy)

**Prof Claire SHOVLIN** (VASCERN HHT European Reference Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust London, UK)

**Dr Patricia SUPPRESSA** (VASCERN HHT European Reference Centre, Azienda Ospedaliero-Universitaria Consorziale di Bari Policlinico-Giovanni XXIII, Bari, Italy)

**Prof Ulrich SURE** (VASCERN HHT European Reference Centre, Essen Center for Rare Diseases, Essen University Hospital, Germany)

**Dr. Sara UGOLINI** (VASCERN HHT European Reference Centre, Department of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy)



Co-funded by  
the Health Programme  
of the European Union